Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
2023 · Leukemia · 126 citations
https://doi.org/10.1038/s41375-023-01829-9
D
Dong‐Wook Kim
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
602
Papers
20.2K
Citations
62
h-index
244
i10-index
Dong‐Wook Kim is an academic researcher from University Health Network. The author has contributed to research in topics: Chronic Myeloid Leukemia Treatments & Chronic Lymphocytic Leukemia Research & Acute Lymphoblastic Leukemia research. The author has an h-index of 62, co-authored 512 publications.
ORCID: 0000-0003-3967-4267Papers by this author
worksSensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay
2011 · Leukemia & lymphoma/Leukemia and lymphoma · 102 citations
https://doi.org/10.3109/10428194.2011.555569
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee
2022 · Journal of Hematology & Oncology · 63 citations
https://doi.org/10.1186/s13045-021-01221-z
Dipeptide species regulate p38MAPK–Smad3 signalling to maintain chronic myelogenous leukaemia stem cells
2015 · Nature Communications · 62 citations
https://doi.org/10.1038/ncomms9039
Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy
2009 · Leukemia & lymphoma/Leukemia and lymphoma · 58 citations
https://doi.org/10.1080/10428190902926973
Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib
2013 · American Journal of Hematology · 56 citations
https://doi.org/10.1002/ajh.23427
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat